Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: BCR–ABL1T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice, Leukemia & Lymphoma, August 2014, Taylor & Francis,
DOI: 10.3109/10428194.2014.940582.
You can read the full text:
Contributors
The following have contributed to this page